Robert Driscoll Analyst PerformanceSenior Vice President, Equity Research at WedbushRobert Driscoll is a stock analyst at Wedbush focused in the medical sector, covering 26 publicly traded companies. Over the past year, Robert Driscoll has issued 45 stock ratings, including buy, hold, and sell recommendations. While full access to Robert Driscoll's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Robert Driscoll's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings57 Last 8 YearsBuy Recommendations77.19% 44 Buy RatingsCompanies Covered26 Unique Companies Ratings Distribution57RatingsDistribution of strong buy, buy, hold, and sell ratings by Robert Driscoll.RatingPercentageCount Strong Buy0.0%0 ratings Buy77.2%44 ratings Hold15.8%9 ratings Sell7.0%4 ratingsOut of 57 total stock ratings issued by Robert Driscoll at Wedbush, the majority (77.2%) have been Buy recommendations, followed by 15.8% Hold and 7.0% Sell.Best & Worst CallsBest Call0000.0%RVMDApr 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%HOWLMar 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ96.2% of companies on NASDAQ25 companiesNYSE3.8% of companies on NYSE1 companyRobert Driscoll, an analyst at Wedbush, currently covers 26 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical25 companies96.2%Manufacturing1 company3.8%Robert Driscoll of Wedbush specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE21 companies80.8%MED - DRUGS4 companies15.4%BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES1 company3.8% About Robert DriscollRobert Driscoll, Ph.D., has over a decade in research and analytics in the life sciences sector – specifically in the area of oncology and more recently in the areas of infectious disease. He is a molecular biologist who received his Ph.D. from the University of Cambridge, and spent six additional years working in the lab at Stanford. He is particularly interested in the development and causes of cancer, as well as the expanding world of immuno-oncology. Since joining Wedbush in 2014, Robert has been covering a number of cutting-edge companies that include Arvinas (ARVN), Kura Oncology (KURA), Arcus Biosciences (RCUS), and IGM Biosciences (IGMS). Robert received his Bachelor’s degree in Biochemistry from the University of Leeds, and his Ph.D. in Cellular and Molecular Biology from the University of Cambridge. He also completed a postdoctoral fellowship at Stanford University.Follow on LinkedIn Robert Driscoll's Ratings History at Wedbush Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsAVTXAvalo Therapeutics5/14/2026Lower Price Target$19.85$34.00Outperform$0.0000.00% ROITNGXTango Therapeutics5/14/2026Boost Price Target$23.72$33.00Outperform$0.0000.00% ROIAPREAprea Therapeutics5/14/2026Lower Price Target$0.90$6.00Outperform$0.0000.00% ROIEIKNEIKN5/12/2026Lower Price Target$9.95$5.00Underperform$0.0000.00% ROICGEMCullinan Therapeutics5/8/2026Boost Price Target$14.96$37.00Outperform$0.0000.00% ROIJANXJanux Therapeutics5/8/2026Lower Price Target$14.30$36.00Outperform$0.0000.00% ROIRVMDRevolution Medicines5/7/2026Boost Price Target$144.46$165.00Outperform$0.0000.00% ROIAVTXAvalo Therapeutics5/6/2026Boost Price Target$16.26$40.00Outperform$0.0000.00% ROIPYXSPyxis Oncology5/5/2026Initiated Coverage$1.76$6.00Outperform$0.0000.00% ROIIDYAIDEAYA Biosciences4/14/2026Boost Price Target$30.82$58.00Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. RVMDRevolution Medicines4/14/2026Reiterated Rating$138.88Outperform$0.0000.00% ROIREPLReplimune Group4/13/2026Reiterated Rating$4.77$2.00Neutral$0.0000.00% ROIRCUSArcus Biosciences4/2/2026Boost Price Target$21.89$41.00Outperform$0.0000.00% ROIEIKNEIKN3/31/2026Reiterated Rating$10.03$7.00Underperform$0.0000.00% ROIIDYAIDEAYA Biosciences3/31/2026Reiterated Rating$33.36$52.00Outperform$0.0000.00% ROIAPREAprea Therapeutics3/31/2026Reiterated Rating$0.74$7.00Outperform$0.0000.00% ROIBDTXBlack Diamond Therapeutics3/17/2026Boost Price Target$2.19$14.00Outperform$0.0000.00% ROICTMXCytomX Therapeutics3/17/2026Boost Price Target$6.75$11.00Outperform$0.0000.00% ROIFHTXFoghorn Therapeutics3/12/2026Reiterated Rating$4.87$10.00Outperform$0.0000.00% ROICGEMCullinan Therapeutics3/11/2026Boost Price Target$14.91$36.00Outperform$0.0000.00% ROIDAWNDay One Biopharmaceuticals3/9/2026Reiterated Rating$21.20$21.50Neutral$0.0000.00% ROIKURAKura Oncology3/6/2026Lower Price Target$8.51$36.00Outperform$0.0000.00% ROITNGXTango Therapeutics3/6/2026Boost Price Target$16.80$19.00Outperform$0.0000.00% ROIDAWNDay One Biopharmaceuticals3/6/2026Downgrade$21.20Hold$0.0000.00% ROIEIKNEIKN2/26/2026Initiated Coverage$14.89$7.00Underperform$0.0000.00% ROIDAWNDay One Biopharmaceuticals2/25/2026Boost Price Target$12.02$30.00Outperform$0.0000.00% ROIARVNArvinas2/24/2026Boost Price Target$11.99$11.00Neutral$0.0000.00% ROIIDYAIDEAYA Biosciences2/18/2026Boost Price Target$30.76$52.00Outperform$0.0000.00% ROITYRATyra Biosciences2/13/2026Boost Price Target$29.60$53.00Outperform$0.0000.00% ROIAPREAprea Therapeutics2/10/2026Lower Price Target$0.64$7.00Outperform$0.0000.00% ROIREPLReplimune Group2/4/2026Boost Price Target$7.35$19.00Outperform$0.0000.00% ROIRVMDRevolution Medicines1/9/2026Reiterated Rating$107.39Outperform$0.0000.00% ROITYRATyra Biosciences12/16/2025Boost Price Target$22.12$37.00Outperform$0.0000.00% ROICGONCG Oncology12/11/2025Initiated Coverage$41.74$70.00Outperform$0.0000.00% ROICGEMCullinan Therapeutics12/9/2025Boost Price Target$12.44$34.00Outperform$0.0000.00% ROIKURAKura Oncology11/14/2025Reiterated Rating$10.68$38.00Outperform$0.0000.00% ROIRVMDRevolution Medicines11/6/2025Boost Price Target$59.34$80.00Outperform$0.0000.00% ROIREPLReplimune Group10/20/2025Upgrade$4.50$18.00Outperform$0.0000.00% ROICRBPCorbus Pharmaceuticals10/20/2025Boost Price Target$19.32$38.00Outperform$0.0000.00% ROIRVMDRevolution Medicines10/17/2025Reiterated Rating$49.68$77.00Outperform$0.0000.00% ROIMillionaire warns: Move your money now (Ad)Larry Benedict, the hedge fund trader who generated $274 million in profits for clients and beat the S&P 500 by 18 times in 2025, says Trump's installation of a new Federal Reserve chair is triggering the most significant shift in U.S. markets in nearly 20 years. Benedict's track record around Fed moves is hard to ignore - 62% from a single position after 2020 rate cuts, 117% in under a month when rate hikes were signaled in 2022, and an 89% gain in 17 days following a Jackson Hole speech. He has already identified the one ticker he believes will be at the center of the coming money flows, and he's sharing it free.Click here to see the ticker Larry Benedict is recommending right nowRVMDRevolution Medicines9/11/2025Boost Price Target$40.45$77.00Outperform$0.0000.00% ROIREPLReplimune Group7/22/2025Reiterated Rating$3.14$4.00Neutral$0.0000.00% ROICBIOCrescent Biopharma7/14/2025Initiated Coverage$12.96$27.00Outperform$0.0000.00% ROIKURAKura Oncology6/20/2025Reiterated Rating$6.06$36.00Outperform$0.0000.00% ROIZNTLZentalis Pharmaceuticals5/15/2025Reiterated Rating$1.18$4.00Neutral$0.0000.00% ROIHOWLWerewolf Therapeutics5/9/2025Lower Price Target$0.82$6.00Outperform$0.0000.00% ROIRVMDRevolution Medicines4/28/2025Reiterated Rating$41.02$67.00Outperform$000.0000.00% ROIZNTLZentalis Pharmaceuticals3/28/2025Reiterated Rating$1.70$4.00Neutral$0.0000.00% ROIGLUEMonte Rosa Therapeutics3/20/2025Reiterated Rating$7.06$17.00Outperform$00.0000.00% ROIARVNArvinas3/12/2025Downgrade$8.30$12.00Neutral$00.0000.00% ROIHOWLWerewolf Therapeutics3/12/2025Reiterated Rating$1.30$8.00Outperform$0.0000.00% ROIDAWNDay One Biopharmaceuticals2/26/2025Reiterated Rating$10.25$32.00Outperform$00.0000.00% ROIKURAKura Oncology2/6/2025Boost Price Target$8.13$36.00Outperform$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James FinancialBMO Capital Markets Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.